Haitian Creole
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
anticancer/infarction
Lyen an sove nan clipboard la
Paj 1 soti nan 19 rezilta yo
Eliminating agent for activated oxygen and free radicals
Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo
Log In / Enskri
FIELD OF THE INVENTION
The present invention relates to agents for eliminating active oxygen and free radicals containing a hydantoin derivative or a pharmaceutically acceptable salt thereof as an effective component. The reduction and elimination of free radicals and activated oxygen in living
Family of aryl, heteroaryl, O-aryl and O-heteroaryl carbasugars
Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo
Log In / Enskri
This invention relates to a family of fluorinated aryl, heteroaryl, O-aryl and O-heteroaryl glycoside compounds, the process for their preparation, as well as the application of same in the pharmaceutical or cosmetic fields, in particular for the treatment or prevention of diabetes and obesity, and
Therapeutic CD47 antibodies
Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo
Log In / Enskri
SEQUENCE LISTING
The present application is being filed along with a sequence listing in electronic format. The sequence listing is provided as a file entitled, "VLX0001-201-US 20131212 SequenceListing_ST25", created on Dec. 11, 2013 which is 90 Kb in size. The information in the electronic format
Therapeutic CD47 antibodies
Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo
Log In / Enskri
SEQUENCE LISTING
The present application is being filed along with a sequence listing in electronic format. The sequence listing is provided as a file entitled, "VLX0001-201-US 20131212 SequenceListing_ST25", created on Dec. 11, 2013 which is 90 Kb in size. The information in the electronic format
Therapeutic CD47 antibodies
Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo
Log In / Enskri
SEQUENCE LISTING
The present application is being filed along with a sequence listing in electronic format. The sequence listing is provided as a file entitled, "VLX0001-201-US 20131212 SequenceListing_ST25", created on Dec. 11, 2013 which is 90 Kb in size. The information in the electronic format
Therapeutic CD47 antibodies
Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo
Log In / Enskri
The present invention relates to antibodies that bind CD47 and their use in treating conditions and disorders, such as ischemia-reperfusion injury (IRI) and cancers, mediated by this receptor.
CD47 is a cell surface receptor comprised of an extracellular IgV set domain, a 5 membrane spanning
Therapeutic CD47 antibodies
Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo
Log In / Enskri
INCORPORATION OF SEQUENCE LISTING
The present application is being filed along with a Sequence Listing in electronic format. The Sequence Listing is provided as a file entitled, "VLX0001-201CIP2 US_SequenceListing", created on Jun. 11, 2015, which is 168,755 bytes in size. The information in the
Therapeutic CD47 antibodies
Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo
Log In / Enskri
BACKGROUND
The present disclosure relates to antibodies that bind CD47, including that of humans and other mammalian species, and their use in treating conditions and disorders, such as ischemia-reperfusion injury (IRI) and cancers, mediated by this receptor.
CD47 is a cell surface receptor
Method of inhibiting cell adhesion
Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo
Log In / Enskri
The present invention relates to an animal cell adhesion inhibitory composition which comprises a 4oxo-3-quinolinecarboxylic acid or 4oxo-3-naphthyridinecarboxylic acid derivative possessing cell adhesion inhibitory activity, a novel 4-oxo-3-quinolinecarboxylic acid derivative and a method of
Quinolonecarboxylic acid derivatives, their production and use
Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo
Log In / Enskri
The present invention relates to an animal cell adhesion inhibitory composition which comprises a 4-oxo-3-quinolinecarboxylic acid or 4-oxo-3-naphthyridinecarboxylic acid derivative possessing cell adhesion inhibitory activity, a novel 4-oxo-3-quinolinecarboxylic acid derivative and a method of
Quinolonecarboxylic acid derivatives and their use
Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo
Log In / Enskri
The present invention relates to an animal cell adhesion inhibitory composition which comprises a 4-oxo-3-quinolinecarboxylic acid or 4-oxo-3-naphthyridinecarboxylic acid derivative possessing cell adhesion inhibitory activity, a novel 4-oxo-3-quinolinecarboxylic acid derivative and a method of
Pharmaceutically acceptable salts of 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide
Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo
Log In / Enskri
BACKGROUND OF THE INVENTION
The present invention relates to pharmaceutically acceptable salts of an amide substituted indazole which are inhibitors of the enzyme poly(ADP-ribose)polymerase (PARP), previously known as poly(ADP-ribose)synthase and poly(ADP-ribosyl)transferase. The compounds of the
Pyridine derivative
Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo
Log In / Enskri
TECHNICAL FIELD
The present invention relates to a pyridine derivative having an ability to act as a neurotrophic factor and a salt thereof.
BACKGROUND ART
It has been suggested that in Alzheimer's disease, which has recently been increasing in prevalence, degeneration and dysfunction of cholinergic
N-(4-carb-amimidophenyl)glycineamide derivatives
Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo
Log In / Enskri
BACKGROUND OF THE INVENTION
The invention relates the field of N-(4-carbamimidophenyl)glycineamide derivatives. In particular, the invention relates to novel N-(4-carbamimidophenyl) glycineamide derivatives that are useful for inhibiting the coagulation factors Xa, IXa, and thrombin induced by the
Aldose reductase inhibitors and uses thereof
Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo
Log In / Enskri
All patents, patent applications and publications cited herein are hereby incorporated by reference in their entirety. The disclosures of these publications in their entireties are hereby incorporated by reference into this application in order to more fully describe the state of the art as known to
Baz done ki pi konplè remèd fèy medsin te apiye nan syans
- Travay nan 55 lang
- Geri èrbal te apiye nan syans
- Remèd fèy rekonesans pa imaj
- Kat entèaktif GPS - tag zèb sou kote (vini byento)
- Li piblikasyon syantifik ki gen rapò ak rechèch ou an
- Search remèd fèy medsin pa efè yo
- Izeganize enterè ou yo ak rete kanpe fè dat ak rechèch la nouvèl, esè klinik ak rive
Tape yon sentòm oswa yon maladi epi li sou remèd fèy ki ta ka ede, tape yon zèb ak wè maladi ak sentòm li itilize kont.
* Tout enfòmasyon baze sou rechèch syantifik pibliye
